Amrubicin
Drug
Celgene Corporation
Total Payments
$30,456
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $30,456 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $30,456 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AR-SCLC-PI-0003 - A Phase II Trial of Ambrucin and Carboplatin with Pegfilgrastim in Patients with Extensive-Stage Small Cell Lung Cancer | Celgene Corporation | $30,456 | 0 |
Top Doctors Receiving Payments for Amrubicin
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Nashville, TN | $30,456 | 1 |
Ad
Manufacturing Companies
- Celgene Corporation $30,456
Product Information
- Type Drug
- Total Payments $30,456
- Total Doctors 0
- Transactions 1
About Amrubicin
Amrubicin is a drug associated with $30,456 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2018 to 2018. In 2018, $30,456 was paid across 1 transactions to 0 doctors.
The most common payment nature for Amrubicin is "Unspecified" ($30,456, 100.0% of total).
Amrubicin is associated with 1 research study, including "AR-SCLC-PI-0003 - A Phase II Trial of Ambrucin and Carboplatin with Pegfilgrastim in Patients with Extensive-Stage Small Cell Lung Cancer" ($30,456).